JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 1
DOI:10.33266/1024-6177-2024-69-1-83-87
R.I. Tamrazov1, 2, R.D. Khusnutdinov2, E.N. Alekhin1, 2, N.V. Averina2,
Yu.S. Pyshkina1, 3, D.А. Pashkov1, 2
Own Experience of using the Radiopharmaceutical 99mTc-sentiskan in Visualization of Sentinel Lymph Nodes in Patients with Breast Cancer
1 Tyumen State Medical University, Tyumen, Russia
2 Medical City, Tyumen, Russia
3 Samara State Medical University, Samara, Russia
Contact person: Yu.S. Pyshkina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the capabilities of the new radiopharmaceutical 99mTc-sentiscan in the visualization of sentinel lymph nodes in patients with breast cancer.
Material and methods: A survey of 178 people diagnosed with breast cancer. Patients were divided into two groups depending on the route of administration of the radiopharmaceutical. The day before surgical treatment, all subjects were injected with a radiopharmaceutical using a syringe with an activity of no more than 120 MBq, in a volume of 0.3‒0.4 ml. The visualized sentinel lymph nodes were marked on the skin using a patented device – «Device for external marking of sentinel lymph nodes during radionuclide visualization». Intraoperative search for sentinel lymph nodes was carried out using gamma detectors Gamma-Finder II or Radical, followed by urgent histological examination.
Results: Radioisotope visualization of sentinel lymph nodes using the domestic radiopharmaceutical 99mTc-sentiscan: in the first group (the drug was administered peritumorally) was 100 %, the average number of visualized lymph nodes in this group was 2.2; in the second group (the drug was administered subareolarly) ‒ 99.1 %, the average number of visualized lymph nodes ‒ 2.6. In the first group of patients, metastatic lesions of sentinel lymph nodes were detected in 8 cases (13.1 %), and in the second group ‒ in 14 (11.9 %). All lymph nodes were mapped in the axillary region on the side of the tumor process.
Conclusion: The possibility of the radiopharmaceutical 99mTc-sentiscan for the identification and biopsy of sentinel lymph nodes in patients with breast cancer was assessed. The use of the domestic 99mTc-sentiscan makes it possible to visualize sentinel lymph nodes in patients with breast cancer and detect their location in 99.1‒100 % of cases. Taking into account the results obtained, the expanded indications for the use of the radiopharmaceutical and the cost of the kits, 99mTc-sentiscan is more preferable for use in clinical practice.
Keywords: sentinel lymph node, breast cancer, scintigraphy, 99mTc-sentiscan
For citation: Tamrazov RI, Khusnutdinov RD, Alekhin EN, Averina NV, Pyshkina YuS, Pashkov DА. Own Experience of using the Radiopharmaceutical 99mTc-sentiskan in Visualization of Sentinel Lymph Nodes in Patients with Breast Cancer. Medical Radiology and Radiation Safety. 2024;69(1):83–87. (In Russian). DOI:10.33266/1024-6177-2024-69-1-83-87
References
1.Kudratova E.A., Fedorov N.M. Epidemiology of Breast Cancer in the Tyumen Region for the Period 2017-2021 During the COVID-19 Pandemic. Molodezhnaya Nauka i Sovremennost: Materialy 88 Mezhdunarodnoy Nauchnoy Konferencii Studentov i Molodyh Uchenyh = Youth science and modernity. Materials of the 88th International Scientific Conference of Students and Young Scientists. 2023. P. 163-165. URL: https://elibrary.ru/item.asp?id=53959934. (Access date: 06.10.2023) (In Russ.).
2.Nartokova A.S.Kh., Koychuyev A.A. Axillary Lymphadenectomy in Surgical Treatment of Breast Cancer. Experience Without Drainage Technique. Nauchnyy Medicinskiy Vestnik Yugry. 2022;32;2:117-118 doi: 10.25017/2306-1367-2022-32-2-117-118 (In Russ.).
3.Babayeva O.G., Kvon T.E., Shevchenko K.Yu., Sidorov S.V., Novikov S.S. Analysis of Relapse-Free and Overall Survival in Oncoplastic and Organ-Preserving Surgeries in Patients with Breast Cancer. Issledovaniya i Praktika v Medicine = Research’n Practical Medicine Journal. 2021;8;4:65-71. doi: 10.17709/2410-1893-2021-8-4-6 (In Russ.).
4.Kuru B. The Adventure of Axillary Treatment in Early Stage Breast Cancer. Eur. J. Breast Health. 2020;16;1:1-15. doi: 10.5152/ejbh.2019.5157.
5.Ermakov A.A., Zikiryahodzhayev A.D., Lazutina T.A., Leontyev A.V., Volchenko N.N., Belyakov M.M., Kaprin A.D., Kostin A.A. Sentinel Lymph Nodes Biopsy in Early Breast Cancer and Melanoma Patients Using “Tehnefit 99mTc” Radioactive Colloid Technetium 99mTc. Zlokachestvennyye Opuholi = Malignant Tumoursis. 2016;3:63-76. doi: 10.18027/2224-5057-2016-3-63-76 (In Russ.).
6.Eldaly A.S., Avila F.R., Torres-Guzman R.A., Maita K., Garcia J.P., Serrano L.P., Forte A.J. Radiomics and Artificial Intelligence in Predicting Axillary Lymph Node Metastasis in Breast Cancer: a Systematic Review. Curr. Med. Imaging. 2023;19;6:564-578. doi: 10.2174/1573405618666220822093226.
7.Khusnutdinov R.D., Alekhin E.N., Averina N.V., Elishev V.G., Tsarev O.N., Novozhenov Y.V., Borodina E.R., Ershova E.V. Sentinel Lymph Nodes Imaging with the Use of Periareolar Injection of Imaging Agent to Patients with Breast Cancer. Akademicheskiy Zhurnal Zapadnoy Sibiri = Academic Journal of West Siberia. 2016;4;65:40-41 (In Russ.).
8.Tamrazov R.I., Neverova E.N., Pavlova V.I., Averina N.V., Alekhin E.N., Khusnutdinov R.D., Korabelnikov M.A. Device for External Marking of Areas of Increased Accumulation of Radiopharmaceuticals with Radionuclide Imaging. Utility Model Patent 218690 U1, 06.06.2023. Application No. 2022115871 dated 06/10/2022 (In Russ.).
9.Bobirca F., Leventer M., Georgescu D.E., Dumitrescu D.A., Alexandru C., Serban D., Valeanu L., Pătrașcu T., Bobircă A. Variability of Sentinel Lymph Node Location in Patients with Trunk Melanoma. Diagnostics (Basel). 2023;13;17:2790. doi: 10.3390/diagnostics13172790.
10.You J.Y., Lee E.S., Lim S.K., Kwon Y., Jung S.Y. Could Axillary Lymph Node Dissection Be Omitted in the Mastectomy Patient with Tumor Positive Sentinel Node? Front Oncol. 2023;13:1181069. doi: 10.3389/fonc.2023.1181069.
11.Barker V.R., Naffouje S.A., Mallory M.A., Hoover S.A., Laronga C. Surgical Management of the Axilla in HR+/HER2- Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database. Ann. Surg. Oncol. 2023. doi: 10.1245/s10434-023-14029-7.
12.Muñoz-Alcaraz M.N., Jiménez-Vílchez A.J., Pérula-de Torres L.Á., Serrano-Merino J., García-Bustillo Á., Pardo-Hernández R., González-Bernal J.J., González-Santos J. Effect of Conservative Rehabilitation Interventions on Health-Related Quality of Life in Women with Upper Limb Lymphedema Secondary to Breast Cancer: A Systematic Review. Healthcare (Basel). 2023;11;18:2568. doi: 10.3390/healthcare11182568.
13.Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Ann. Surg. 1994;220;3:391-398. doi: 10.1097/00000658-199409000-00015.
14.McIntosh S.A., Purushotham A.D. Lymphatic Mapping and Sentinel Node Biopsy in Breast Cancer. Br. J. Surg. 1998;85;10:1347-1356. doi: 10.1046/j.1365-2168.1998.00934.x.
15.Veronesi U., Paganelli G., Galimberti V., Viale G., Zurrida S., Bedoni M., Costa A., de Cicco C., Geraghty J.G., Luini A., Sacchini V., Veronesi P. Sentinel-Node Biopsy to Avoid Axillary Dissection in Breast Cancer with Clinically Negative Lymph-Nodes. Lancet. 1997;349;9069:1864-1867. doi: 10.1016/S0140-6736(97)01004-0.
16.Khusnutdinov R.D., Alekhin E.N., Fedorov N.M., Zotov P.B., Averina N.V., Borodina E.R., Novozhenov Y.V., Teffenberg D.V., Basova T.S. Visualization of Sentinel Lymph Nodes Using Radiopharmaceutical «Nanotop 99mТс » «Technefit 99mТс » in Patients with Breast Cancer. Scientific Forum. Siberia. 2020;6;1:42-43 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Tamrazov R.I.: development of the research concept, development of the research design; writing and scientific editing of the text; Khusnutdinov R.D.: development of research design, conduct of research, development and modification of research methods, collection and analysis of literary material, staatistical data processing, writing and scientific editing of the text; Alekhin E.N.: development of research design, conduct of research, development and modification of research methods, collection and analysis of literary material, statistical data processing, writing and scientific editing of the text; Averina N.V.: conducting research, developing and modifying research methods; Pyshkina Yu.S.: collection and analysis of literary material, statistical data processing, writing and scientific editing of the text; Pashkov D.A.: conducting research, developing and modifying research methods.
Article received: 20.10.2023. Accepted for publication: 27.11.2023.